IP Library Granted Patent US 8,999,977
Granted Patent B2
US 8,999,977 · App. 13/791,832 · Granted Apr 7, 2015

Bridged heterocyclic compounds and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,999,977
App. No.
13/791,832
Granted
Apr 7, 2015
Kind
B2
Abstract

This disclosure relates to new compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new bridged heterocyclic [4,3-b]indole compounds. Pharmaceutical compositions are also provided. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

Claims (37)

1. A compound of the formula (E):

or a salt thereof, wherein:

R 1 is H, hydroxyl, unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted C 2 -C 8 alkenyl, substituted or unsubstituted C 2 -C 8 alkynyl, perhaloalkyl, acyl, acyloxy, carbonylalkoxy, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, C 1 -C 8 perhaloalkoxy, alkoxy, aryloxy, thioalkyl, substituted or unsubstituted amino, acylamino, aminoacyl, aminocarbonylamino, aminocarbonyloxy, aminosulfonyl, sulfonylamino, sulfonyl or carbonylalkylenealkoxy;

R 2 is H, hydroxyl, alkoxy or substituted or unsubstituted C 1 -C 8 alkyl;

each R 3a and R 3b is independently H, substituted or unsubstituted C 1 -C 8 alkyl, halo, cyano, nitro, hydroxyl, alkoxy, amino, substituted amino, cycloalkyl, acylamino or acyloxy or R 3a and R 3b are taken together to form a cycloalkyl moiety or a carbonyl moiety;

each X 7 , X 8 , X 9 and X 10 is independently N or CR 4 ;

m and q are independently 0 or 1;

p is 1 or 2;

n is 1;

each R 4 is independently H, hydroxyl, nitro, cyano, halo, C 1 -C 8 perhaloalkyl, substituted or unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted C 2 -C 8 alkenyl, substituted or unsubstituted C 2 -C 8 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, C 1 -C 8 perhaloalkoxy, C 1 -C 8 alkoxy, aryloxy, carboxyl, thiol, carbonylalkoxy, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, thioalkyl, substituted or unsubstituted amino, acylamino, aminoacyl, aminocarbonylamino, aminocarbonyloxy, aminosulfonyl, sulfonylamino, sulfonyl, carbonylalkylenealkoxy, alkylsulfonylamino or acyl;

each R 8a , R 8b , R 8c , R 8d , R 8e and R 8f , where present, is independently H, hydroxyl, C 1 -C 8 alkyl, carboxy, carbonylalkoxy, is taken together with the carbon to which it is attached and a geminal R 8(a-f) to form a cycloalkyl moiety or a carbonyl moiety, is taken together with a geminal R 8(a-f) to form a methylene or a substituted methylene, or is taken together with a vicinal R 8(a-f) and the carbon atoms to which they are attached to form a substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted C 3 -C 8 cycloalkenyl or substituted or unsubstituted heterocyclyl moiety;

R10 is H, hydroxyl, alkoxy or a substituted or unsubstituted C 1 -C 8 alkyl; and

Q is aminoacyl group, wherein the aminoacyl is —NRaC(O)Rb where each Ra and Rb group is independently selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic or substituted heterocyclic.

2. The compound of claim 1 , or a salt thereof, wherein Q is aminoacyl of the formula —NR a C(O)R b where R a is H or alkyl and R b is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic or substituted heterocyclic.

3. The compound of claim 2 , or a salt thereof, wherein R a is H.

4. The compound of claim 3 , or a salt thereof, wherein R b is unsubstituted or substituted heteroaryl.

5. The compound of claim 4 , or a salt thereof, wherein X 7 , X 8 , X 9 and X 10 are CR 4 .

6. The compound of claim 5 , or a salt thereof, wherein each R 4 is independently H, halo, C 1 -C 8 perhaloalkyl, or substituted or unsubstituted C 1 -C 8 alkyl.

7. The compound of claim 6 , or a salt thereof, wherein R 1 is H, unsubstituted C 1 -C 8 alkyl, acyl or carbonylalkoxy.

8. The compound of claim 7 , or a salt thereof, wherein each R 2 , R 10 , R 3a and R 3b is H.

9. The compound of claim 8 , or a salt thereof, wherein p is 1.

10. The compound of claim 9 , or a salt thereof, wherein each R 8a , R 8b , R 8C , R 8d , R 8e and R 8 f , where present, is H.

11. The compound of claim 1 , or a salt thereof, wherein X 7 , X 8 , X 9 and X 10 are CR 4 .

12. The compound of claim 11 , or a salt thereof, wherein each R 4 is independently H, halo, C 1 -C 8 perhaloalkyl, or substituted or unsubstituted C 1 -C 8 alkyl.

13. The compound of claim 1 , or a salt thereof, wherein at least one of X 7 , X 8 , X 9 and X 10 is N.

14. The compound of claim 1 , or a salt thereof, wherein R 1 is H, unsubstituted C 1 -C 8 alkyl, acyl or carbonylalkoxy.

15. The compound of claim 14 , or a salt thereof, wherein R 1 is unsubstituted C 1 -C 8 alkyl.

16. The compound of claim 15 , or a salt thereof, wherein each R 2 , R 10 , R 3a and R 3b is H.

17. The compound of claim 16 , or a salt thereof, wherein p is 1.

18. The compound of claim 1 , or a salt thereof, wherein each R 8a , R 8b , R 8c , R 8d , R 8e and R 8f , where present, is independently H, hydroxyl, unsubstituted C 1 -C 4 alkyl, is taken together with the carbon to which it is attached and a geminal R 8(a-f) to form a carbonyl moiety or is taken together with a geminal R 8(a-f) to form a methylene or a substituted methylene.

19. The compound of claim 18 , or a salt thereof, wherein each R 8a , R 8b , R 8c , R 8d , R 8e and R 8f , where present, is H.

20. The compound of claim 1 , or a salt thereof, wherein the compound is selected from the group consisting of:

21. The compound of claim 1 , or a salt thereof, wherein the compound is:

22. A pharmaceutical composition comprising a compound according to claim 1 or a salt thereof, and a pharmaceutically acceptable carrier.

23. A pharmaceutical composition comprising a compound according to claim 20 or a salt thereof, and a pharmaceutically acceptable carrier.

24. A pharmaceutical composition comprising a compound according to claim 21 or a salt thereof, and a pharmaceutically acceptable carrier.

25. A kit comprising a compound according to claim 1 or a salt thereof.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Sep 28, 2016
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: MEDIVATION PROSTATE THERAPEUTICS, INC.; MEDIVATION TECHNOLOGIES, INC.
Reel/Frame 040181/0177 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Sep 4, 2015
From: MEDIVATION TECHNOLOGIES, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 036553/0925 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2014
From: HUNG, DAVID T.; PROTTER, ANDREW ASHER; CHAKRAVARTY, SARVAJIT; JAIN, RAJENDRA PARASMAL
To: MEDIVATION TECHNOLOGIES, INC.
Reel/Frame 034065/0110 →